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Mediastinal nonseminomatous germ-cell tumor(NSGCT) has a very poor prognosis.1 We report 3cases of mediastinal NSGCT successfully treatedwith induction chemotherapy, radical surgical in-
tervention, and high-dose chemotherapy (HDCT) supported by
autologous peripheral blood stem-cell transplantation (PBSCT).
Clinical Summary
Three young men with large mediastinal NSGCTs met the require-
ments to enter the study (Figure 1 and Table 1). All patients were
given pathologic diagnoses of NSGCT on the basis of needle
biopsy and showed increased alpha-fetoprotein (AFP) levels. Tes-
ticular ultrasonography was performed to rule out testicular pri-
maries.
Planned treatment began with induction chemotherapy consist-
ing of cisplatin, etoposide, and bleomycin. Cisplatin was admin-
istered at a dose of 20 mg · m2 on days 1 through 5, etoposide
was administered at a dose of 100 mg · m2 on days 1 through 5,
and bleomycin was administered at a dose of 20 mg · m2 on days
1, 8, and 15. The bleomycin, etoposide, and cisplatin (BEP)
induction chemotherapy was delivered for 4 cycles at 2-week
intervals. During hematologic recovery after the third or fourth
cycle of the induction chemotherapy, peripheral blood stem cells
were collected by means of apheresis with a continuous blood cell
separator.
Patients underwent a median sternotomy with or without an-
terolateral thoracotomy within 6 weeks of completing induction
chemotherapy. Total thymectomy with combined resection of the
invaded surrounding tissue was carried out.
After full recovery from the operation, patients received HDCT
consisting of carboplatin, ifosfamide, and etoposide. Carboplatin
was administered at a dose of 400 mg · m2 on days 7, 5, and
3. Ifosfamide was administered at a dose of 3 g · m2 on days 7
through 3. Etoposide was administered at a dose of 500 mg · m2
on days 7, 5, and 3. PBSCT containing peripheral blood
stem cells (3.6-11.2  106 CD34 cells per kilogram) was per-
formed 72 hours after completing HDCT (day 0) and just after
administration of methylprednisolone (250 mg). Granulocyte
colony-stimulating factor was administered subcutaneously at a
dose of 250 g beginning on day 1 and continued until an absolute
neutrophil count of 1000 L was achieved.
Results
During the BEP induction chemotherapy, 2 patients had a partial
response, and 1 patient had stable disease, as determined radio-
graphically. AFP levels were decreased by BEP in all 3 patients
but normalized only in 1 patient.
All 3 patients underwent radical intervention, with complete
resections of the residual mediastinal tumors combined with in-
vaded surrounding tissue. Pathologic diagnoses of the excised
tumor were persistent NSGCT in 2 patients and teratoma in 1
patient. No perioperative complications were encountered. AFP
levels became normal within 6 weeks after the operation in all 3
patients.
All 3 patients received HDCT supported by PBSCT 9 to 14
weeks after the operation without dose modification. As expected,
all patients showed grade 4 neutropenia and thrombocytopenia.
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Figure 1. Chest computed tomographic scan showing a large
anterior mediastinal tumor (patient 2). It was pathologically di-
agnosed as nonseminomatous germ-cell tumor by means of nee-
dle biopsy.
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They required platelet transfusions and supportive care for neutro-
penic fevers. Nonhematologic toxicity included grade 3 diarrhea in
1 patient, grade 2 alopecia in 3 patients, and grade 2 proteinuria in
2 patients.
They were discharged 16 to 17 days after PBSCT in excellent
condition. They are currently alive 77, 74, and 34 months postop-
eratively, with no sign of recurrence.
Discussion
Although histologically and serologically identical to more com-
mon testicular counterparts, mediastinal NSGCT has a distinctly
poorer prognosis.1 Recent studies have suggested that HDCT with
autologous hematopoietic stem-cell support provides better sur-
vival than conventional dose chemotherapy for patients with re-
lapsed or refractory testicular NSGCTs.2 However, HDCT has not
been widely applied in patients with mediastinal NSGCTs. Takeda
and associates3 used PBSCT to support HDCT in 2 patients with
choriocarcinoma and 1 patient with embryonal cell carcinoma.
These 3 patients were alive and disease free for 25 to 73 months.
Intensive platinum-based induction chemotherapy followed by
surgical resection appears to be the current standard treatment for
mediastinal NSGCT. An Indiana University group treated 79 pa-
tients with mediastinal NSGCTs with this strategy and reported an
overall survival rate of 61% after an average follow-up of 48
months.4 The MD Anderson Cancer Center reported that the
2-year survival was 72% in 11 patients.5 In theses reports, oper-
ations for patients whose markers had not normalized with induc-
tion chemotherapy was usually futile. It was also recognized that
a pathologic finding of persistent viable NSGCT in the residual
mass predicted the worst prognosis. Among the 3 patients in our
study, 2 had increased AFP levels after induction chemotherapy
and had pathologically persistent viable NSGCT in the residual
tumor. Therefore we believe that HDCT with PBSCT played an
important role in achieving long-term survival (77, 74, and 34
months) in our patients. Further investigations are warranted to
clarify its effectiveness.
References
1. Dulmet EM, Macchiarini P, Suc B, Verley JM. Germ cell tumors of the
mediastinum. A 30-year experience. Cancer. 1993;72:1894-901.
2. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W. High-dose versus
conventional-dose chemotherapy as first-salvage treatment in patients
with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann
Oncol. 2002;13:599-605.
3. Takeda S, Miyoshi S, Ohta M, Minami M, Masaoka A, Matsuda H.
Primary germ cell tumors in the mediastinum. A 50-year experience at
a single Japanese institution. Cancer. 2002;97:367-76.
4. Kesler KA, Rieger KM, Ganjoo KN, Sharma M, Fineberg NS, Einhorn
LH, et al. Primary mediastinal nonseminomatous germ cell tumors: the
influence of postchemotherapy pathology on lung-term survival after
surgery. J Thorac Cardiovasc Surg. 1999;118:692-701.
5. Walsh GL, Taylor GD, Nesbitt JC, Amato RJ. Intensive chemotherapy
and radical resections for primary nonseminomatous mediastinal germ
cell tumors. Ann Thorac Surg. 2000;69:337-44.
TABLE 1. Characteristics of 3 patients with NSGCT of the mediastinum
Patient 1 Patient 2 Patient 3
Age (y) 26 27 20
Sex Male Male Male
Tumor size (cm)
Pre-CT 9.5  7.2 12.3  7.5 15.0  9.0
Post-CT 4.5  4.5 11.0  6.0 4.0  3.0
Response PR SD PR
Surgery
Combined resection Rt lung (partial) Pericardium Rt phrenic nerve
Lt BCV
Rt lung (partial)
Pathology
Pre-CT needle biopsy NSGCT NSGCT NSGCT
Excised tumor after CT Teratoma Persistent NSGCT Persistent NSGCT
AFP (ng/mL)
Pre-CT 1044 570.3 1180
Post-CT 4.6 45.9 185.3
Pre-HDCT 3.2 1.4 2.4
Current 3.8 1.2 1.4
Outcome 77 mo alive 74 mo alive 34 mo alive
NSGCT, Nonseminomatous germ-cell tumor; AFP, alpha-fetoprotein; CT, chemotherapy; HDCT, high-dose chemotherapy; PR, partial response; SD, stable
disease; BCV, brachiocephalic vein.
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